全文获取类型
收费全文 | 1365篇 |
免费 | 118篇 |
国内免费 | 38篇 |
专业分类
儿科学 | 7篇 |
妇产科学 | 7篇 |
基础医学 | 50篇 |
口腔科学 | 2篇 |
临床医学 | 93篇 |
内科学 | 75篇 |
皮肤病学 | 1篇 |
神经病学 | 501篇 |
特种医学 | 12篇 |
外科学 | 14篇 |
综合类 | 52篇 |
预防医学 | 34篇 |
眼科学 | 1篇 |
药学 | 551篇 |
中国医学 | 108篇 |
肿瘤学 | 13篇 |
出版年
2023年 | 11篇 |
2022年 | 27篇 |
2021年 | 30篇 |
2020年 | 30篇 |
2019年 | 41篇 |
2018年 | 42篇 |
2017年 | 49篇 |
2016年 | 43篇 |
2015年 | 58篇 |
2014年 | 67篇 |
2013年 | 153篇 |
2012年 | 72篇 |
2011年 | 89篇 |
2010年 | 76篇 |
2009年 | 73篇 |
2008年 | 81篇 |
2007年 | 49篇 |
2006年 | 56篇 |
2005年 | 48篇 |
2004年 | 36篇 |
2003年 | 40篇 |
2002年 | 35篇 |
2001年 | 33篇 |
2000年 | 13篇 |
1999年 | 9篇 |
1998年 | 12篇 |
1997年 | 24篇 |
1996年 | 21篇 |
1995年 | 16篇 |
1994年 | 15篇 |
1993年 | 9篇 |
1992年 | 13篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 8篇 |
1988年 | 13篇 |
1987年 | 8篇 |
1986年 | 5篇 |
1985年 | 11篇 |
1984年 | 14篇 |
1983年 | 10篇 |
1982年 | 15篇 |
1981年 | 12篇 |
1980年 | 11篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 2篇 |
1973年 | 3篇 |
1972年 | 3篇 |
排序方式: 共有1521条查询结果,搜索用时 0 毫秒
21.
①目的:了解抗抑郁药应用状况及变化趋势。②方法:对青岛大学医学院附属医院2001~2002年抗抑郁药应用的数据资料进行统计、分析。③结果:抗抑郁药的用药金额及用药频度逐年增加。④结论:我院抗抑郁药用药基本合理;我国抗抑郁药市场前景广阔。 相似文献
22.
23.
Major depressive disorder (MDD) is a common and debilitating mental illness, which leads to serious functional impairment in patients, and treatment-wise, there are currently a number of different classes of antidepressants already on the market. However, emerging evidence from numerous clinical trials has confirmed that there is still an unmet need for antidepressant efficacy in terms of response and remission. Approximately only 30% of patients with MDD may remit after adequate treatment with antidepressants in clinical practice. The drawbacks of the currently available antidepressants also include inadequate overall efficacy, safety issues and the lag prior to onset of clinical improvement. The need for new agents with novel mechanisms of action has led to the development of several newer antidepressants including vilazodone, edivoxetine, ketamine, atomoxetine and vortioxetine, which have been approved for the treatment of MDD. However, the efficacy and safety of these next-generation antidepressants, in clinical trials, are still unsatisfactory. This paper provides a brief updated overview of the progress and critical limitations in the development of novel antidepressants. 相似文献
24.
Yi-Wei Yeh Pei-Shen Ho Shin-Chang Kuo Chun-Yen Chen Chih-Sung Liang Che-Hung Yen Chang-Chih Huang Kuo-Hsing Ma Chyng-Yann Shiue Wen-Sheng Huang Jia-Fwu Shyu Fang-Jung Wan Ru-Band Lu San-Yuan Huang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(7)
Background:
Many lines of evidence suggest the role of serotonin transporter (SERT)-mediated reuptake of serotonin in the pathophysiology and treatment of major depressive disorder (MDD). This study aimed to examine whether the pretreatment of SERT binding potential or SERT binding ratio between terminal projection regions relative to the midbrain raphe nuclei was associated with treatment outcomes to SERT-targeted antidepressants.Methods:
We recruited 39 antidepressant-naïve patients with MDD and 39 heathy controls. Positron emission tomography with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) was used to measure in vivo SERT availability prior to antidepressant treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was use to assess the severity of depression from baseline to week 6. All the patients with MDD had HDRS scores of 18 or more.Results:
Pretreatment SERT binding in the thalamus and striatum positively correlated with an early reduction in HDRS scores at week 3. Nonresponders and dropout patients showed a proportionate reduction in SERT binding in the terminal projection regions and midbrain compared to healthy controls. In contrast, a disproportionate reduction in SERT binding in the terminal projection regions relative to midbrain was observed in responders.Conclusions:
The results of this study suggested that a disproportionate reduction in SERT binding between terminal projection regions and midbrain may predict better treatment outcomes in patients with MDD. 相似文献25.
Christoph Josef Spindelegger Konstantinos Papageorgiou Renate Grohmann Rolf Engel Waldemar Greil Anastasios Konstantinidis Marcus Willy Agelink Stefan Bleich Eckart Ruether Sermin Toto Siegfried Kasper 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2015,18(4)
26.
27.
Michael Camilleri 《Mayo Clinic proceedings. Mayo Clinic》2018,93(12):1858-1872
Irritable bowel syndrome (IBS) is associated with diverse pathophysiologic mechanisms. These mechanisms include increased abnormal colonic motility or transit, intestinal or colorectal sensation, increased colonic bile acid concentration, and superficial colonic mucosal inflammation, as well as epithelial barrier dysfunction, neurohormonal up-regulation, and activation of secretory processes in the epithelial layer. Novel approaches to treatment include lifestyle modification, changes in diet, probiotics, and pharmacotherapy directed to the motility, sensation, and intraluminal milieu of patients with IBS. Despite recent advances, there is a need for development of new treatments to relieve pain in IBS without deleterious central or other adverse effects. 相似文献
28.
29.
Serotonergic mechanisms are involved in antidepressant‐like effects of bisbenzylisoquinolines liensinine and its analogs isolated from the embryo of Nelumbo nucifera Gaertner seeds in mice 下载免费PDF全文
30.
Synergistic interaction between diene valepotriates from Valeriana glechomifolia Meyer (Valerianaceae) and classical antidepressants: an isobolographic analysis 下载免费PDF全文